Overview
Anne Favret is a Hematologist and an Oncologist in Leesburg, Virginia. Dr. Favret is rated as an Experienced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Myelodysplastic Syndrome (MDS), and HER-2 Positive Breast Cancer.
Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
44035 Riverside Pkwy, Suite 300, Leesburg, VA 20176
3700 Joseph Siewick Dr, Suite 408, Fairfax, VA 22033
Additional Areas of Focus
Dr. Favret has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
5 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.
Johns Hopkins Children's Center
Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Pediatric Low-Grade Glioma (pLGG).
Inova Health Care Services
Adam Cohen is an Oncologist in Fairfax, Virginia. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioblastoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, Bone Marrow Aspiration, and Liver Embolization. Dr. Cohen is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Breast CancerDr. Favret isDistinguished. Learn about Breast Cancer.
- HER-2 Positive Breast CancerDr. Favret isDistinguished. Learn about HER-2 Positive Breast Cancer.
- Inflammatory Breast CancerDr. Favret isDistinguished. Learn about Inflammatory Breast Cancer.
- Myelodysplastic Syndrome (MDS)Dr. Favret isDistinguished. Learn about Myelodysplastic Syndrome (MDS).
- Paget Disease of the BreastDr. Favret isDistinguished. Learn about Paget Disease of the Breast.
- Triple-Negative Breast CancerDr. Favret isDistinguished. Learn about Triple-Negative Breast Cancer.
- Advanced
- Adult Immune ThrombocytopeniaDr. Favret isAdvanced. Learn about Adult Immune Thrombocytopenia.
- Adult Soft Tissue SarcomaDr. Favret isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- AgranulocytosisDr. Favret isAdvanced. Learn about Agranulocytosis.
- Anal CancerDr. Favret isAdvanced. Learn about Anal Cancer.
- AngiosarcomaDr. Favret isAdvanced. Learn about Angiosarcoma.
- B-Cell LymphomaDr. Favret isAdvanced. Learn about B-Cell Lymphoma.
- Experienced
- Acute Lymphoblastic Leukemia (ALL)Dr. Favret isExperienced. Learn about Acute Lymphoblastic Leukemia (ALL).
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Favret isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Acute Promyelocytic LeukemiaDr. Favret isExperienced. Learn about Acute Promyelocytic Leukemia.
- ALK-Positive Non-Small Cell Lung CancerDr. Favret isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.

